GLUE · Monte Rosa Therapeutics Inc
United States · RS rating 23 · As of 2026-11-03
| Price | 10.41 USD |
|---|---|
| 1-day change | -2.1% |
| RS rating (overall / 1M / 3M / 12M) | 23 / 62 / 18 / 37 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 6 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -60.6% |
| Sales growth Q/Q | -78.2% |
| Distance from 52-week high | +58.9% |
| Market cap (USD) | $1.6B |